Associate Professor, Medicine, Stony Brook University SOM
Oncology
Dr. Shenhong Wu, MD
|
|
Give Review
Dr. Shenhong Wu practices Oncology. He researched medicine at Wenzhou Medical College. Shenhong is also a published MD. He has 21 paper published. The most recent paper is: Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma. He is registered with Medicare and accepts Medicare payments.
Publications
- Incidence and risk of xerosis with targeted antiCancer therapies.
- Incidence and Risk of High-grade Stomatitis with mTOR Inhibitors in Cancer Patients.
- Efficacy of Skin-Directed Therapy for Cutaneous Metastases From Advanced Cancer: A Meta-Analysis.
- Altered cytokine and chemokine profiles in multiple myeloma and precursor disease.
- Incidence and risk of rash to mTOR inhibitors in Cancer patients - a meta-analysis of randomized controlled trials.
- Alopecia With Endocrine Therapies in Patients With Cancer.
- Pruritus in patients treated with targeted Cancer therapies: Systematic review and meta-analysis.
- Pursuing the curative blueprint for early myeloma.
- Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-Analysis.
- Risk of liver toxicity with the angiogenesis inhibitor pazopanib in Cancer patients.
- Pruritus to antiCancer agents targeting the EGFR, BRAF, and CTLA-4.
- The risk of rash associated with ipilimumab in patients with Cancer: A systematic review of the literature and meta-analysis.
- The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-Analysis.
- Rash to the mTOR Inhibitor Everolimus: Systematic Review and Meta-Analysis.
- The risk of nail changes with epidermal growth factor receptor inhibitors: A systematic review of the literature and meta-Analysis.
- AntiCancer therapy-induced adverse events: practicing damage control.
- Risk of rash in Cancer patients treated with vandetanib: systematic review and meta-analysis.
- Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.
- Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in Cancer patients: a meta-analysis.
- Update on the treatment of metastatic clear cell and non-clear cell renal cell Carcinoma.
Schools
Wenzhou Medical College
Yale Ubridgeport Hospital
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
National Institutes of Health Clinical Center -
Wenzhou Medical College
Hospital
-
Stony Brook University Medical Center
Drug Facts
| NPI NUMBER | 1235233636 | |
| NPPES Provider LastName | WU | |
| NPPES Provider FirstName | SHENHONG | |
| NPPES Provider ZIPCode | 11794 | |
| NPPES Provider State | NY | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 711.0 | |
| Distinct Opioid Count | 6.0 | |
| Opioid Claim Count | 96.0 | |
| Percent Opioid Claims | 13.5 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1235233636 |
| Last Name Of The Provider | WU |
| First Name Of The Provider | SHENHONG |
| View All |
Similar Doctors
|
|
Dr. Sunny K. Philip Jr., MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stefan Madajewicz, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Amna F. Sher, MD |